A novel insulin that releases over several days showed similar efficacy to standard insulin but without an advantage for hypoglycemia in its first full phase III study, drugmaker Novo Nordisk announced.
http://www.medpagetoday.com/Endocrinology/Diabetes/23030
Encouraging results in more than one respect - weight loss, tolerance and reduces CV risk... sounds too good to be true! 8)
http://www.medpagetoday.com/Endocrinology/Diabetes/23030
Encouraging results in more than one respect - weight loss, tolerance and reduces CV risk... sounds too good to be true! 8)
